Neoadjuvant immune checkpoint blockade triggers persistent and systemic T(reg) activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Blomberg, Olga S., Kos, Kevin, Spagnuolo, Lorenzo, Isaeva, Olga I., Garner, Hannah, Wellenstein, Max D., Bakker, Noor, Duits, Danique E.M., Kersten, Kelly, Klarenbeek, Sjoerd, Hau, Cheei-Sing, Kaldenbach, Daphne, Raeven, Elisabeth A.M., Vrijland, Kim, Kok, Marleen, de Visser, Karin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114978/
https://www.ncbi.nlm.nih.gov/pubmed/37089449
http://dx.doi.org/10.1080/2162402X.2023.2201147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114978/
https://www.ncbi.nlm.nih.gov/pubmed/37089449
http://dx.doi.org/10.1080/2162402X.2023.2201147

Ejemplares similares